The global adrenogenital syndrome (AGS) treatment market, valued at $13.4 billion in 2024, is projected to grow at a CAGR of 5.4%, reaching $19.4 billion by 2031. This market focuses on managing AGS, a group of inherited adrenal disorders affecting hormone production, through pharmacological therapies like corticosteroids and mineralocorticoids, as well as surgical interventions for complications. As awareness and diagnostic techniques improve, the demand for effective treatments continues to rise, highlighting the market's importance in enhancing the quality of life for individuals with AGS.
